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Abstract
Background: Genetic analysis of the human prion protein gene (PRNP) in suspect cases of Creutzfeldt-Jakob
disease (CJD) is necessary for accurate diagnosis and case classification. Previous publications on the genetic
variation at the PRNP locus have highlighted the presence of numerous polymorphisms, in addition to the well
recognised one at codon 129, with significant variability between geographically distinct populations. It is
therefore of interest to consider their influence on susceptibility or the clinico-pathological disease phenotype.
This study aimed to characterise the frequency and effect of PRNP open reading frame polymorphisms other than
codon 129 in both disease and control samples sourced from the United Kingdom population.
Methods: DNA was extracted from blood samples and genetic data obtained by full sequence analysis of the
prion protein gene or by restriction fragment length polymorphism analysis using restriction enzymes specific to
the gene polymorphism under investigation.
Results: 147 of 166 confirmed cases of variant CJD (vCJD) in the UK have had PRNP codon 129 genotyping and
all are methionine homozygous at codon 129; 118 have had full PRNP gene sequencing. Of the latter, 5 cases have
shown other polymorphic loci: at codon 219 (2, 1.69%), at codon 202 (2, 1.69%), and a 24 bp deletion in the
octapeptide repeat region (1, 0.85%). E219K and D202D were not found in sporadic CJD (sCJD) cases and
therefore may represent genetic risk factors for vCJD.
Genetic analysis of 309 confirmed UK sCJD patients showed codon 129 genotype frequencies of MM: 59.5% (n
= 184), MV: 21.4% (n = 66), and VV: 19.1% (n = 59). Thirteen (4.2%) had the A117A polymorphism, one of which
also had the P68P polymorphism, four (1.3%) had a 24 bp deletion, and a single patient had a novel missense
variation at codon 167. As the phenotype of this latter case is similar to sCJD and in the absence of a family history
of CJD, it is unknown whether this is a form of genetic CJD, or simply a neutral polymorphism.
Conclusions: This analysis of PRNP genetic variation in UK CJD patients is the first to show a comprehensive
comparison with healthy individuals (n = 970) from the same population, who were genotyped for the three most
common variations (codon 129, codon 117, and 24 bp deletion). These latter two genetic variations were equally
frequent in UK sCJD or vCJD cases and a normal (healthy blood donor) UK population.
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Background
At the time of this study, there were 166 confirmed cases
of vCJD in the UK, and a further 44 patients in other coun-
tries. (For current UK and worldwide figures see http://
www.cjd.ed.ac.uk) The widely accepted hypothesis is that
vCJD was initially acquired through dietary infection with
bovine produce contaminated with the infectious agent of
bovine spongiform encephalopathy (BSE) [1,2]. Addi-
tionally, secondary cases have resulted from blood trans-
fusion [3,4]. The proposed agent (designated a 'prion')
has not been fully characterised but disease and infectivity
are generally associated with an abnormally folded form
(designated PrPSc) of the host encoded prion protein
(PrPC) [5]. Variant CJD shows marked differences in clin-
ical presentation [6] and neuropathology [7] when com-
pared with sporadic CJD (sCJD) which has a worldwide
distribution affecting approximately 1-2 cases per million
population per year and has an unknown aetiology. In
comparison to sCJD, vCJD typically occurs in younger
individuals (median ages of onset: 66 & 26 years respec-
tively) and with a longer disease duration (median dura-
tions: 4 and 14 months respectively). There are two other
forms of CJD: genetic and iatrogenic. Genetic CJD (gCJD)
is an autosomal dominant inherited illness related to
underlying mutations of the prion protein gene (PRNP).
There are other genetic human prion diseases (Fatal
Familial Insomnia (FFI), and Gerstmann Sträussler
Scheinker syndrome (GSS)) traditionally separated from
gCJD on clinico-pathological grounds, but which are
related by certain common core features and an underly-
ing causal PRNP mutation. Iatrogenic CJD (iCJD) results
from the accidental person-to-person (medical or surgi-
cal) transmission of other forms of CJD.
Genetic analysis of the sCJD and vCJD disease cohort has
an important role in accurate diagnostic classification,
especially as genetic prion disease cannot always be differ-
entiated clinically from other forms of prion disease and
a family history is absent in up to about 50% of cases [8].
The gene coding for prion protein, PRNP, is a key target
for analysis. This gene is highly conserved between mam-
malian species indicating an important biological role for
the prion protein, but PRNP shows significant variation at
the individual level in humans [9]. Over twenty missense
and nonsense mutations have been identified in the open
reading frame (ORF) that have been linked to genetic
prion disease phenotypes [10]. Other polymorphic sites
in  PRNP  (over twenty examples) that are not directly
linked to a disease phenotype have been identified
through analysis of suspected CJD cases and other popu-
lations. These polymorphisms may have disease modulat-
ing capacities and these effects may vary according to the
population under investigation. The conversion of PrPC to
PrPSc is thought to involve some form of oligomerisation
and the melting and refolding of the peptide chains. It is
therefore possible that any changes to the amino-acid
sequence could alter the thermodynamic stability of the
protein and affect the kinetics of structural conversions
[11].
The  PRNP  polymorphic residue at codon 129 (ATG-
methionine to GTG-valine, M129V) has been studied
extensively. Variation in the genotype frequencies occurs
according to geographical region. In most countries stud-
ied, the MM and MV frequencies are approximately 40-
50% however there is a large difference seen in Japan
where the normal population frequencies are: MM 92%,
MV 8%, and VV 0% [12]. Genotype data from other coun-
tries suggest a gradual increase in MM genotype frequency
from West to East which may reflect the historical human
migrations [12]. It has been shown that M129V may affect
susceptibility to prion diseases [13], the incubation
period in acquired forms [14,15] and the clinico-patho-
logical phenotype [16]. Codon 129 homozygosity is con-
sidered a risk factor for human prion disease: while ~40%
of the normal population is MM, ~70% of sCJD patients,
and all clinical vCJD patients tested to date have this gen-
otype [17]. Homozygosity has also been shown to be a
risk factor, and reduces the incubation time, for both
human growth hormone associated iCJD [14] and kuru
[15] (an historical disease of the Fore linguistic tribe of
Papua New Guinea transmitted by endocannibalism). In
some circumstances, the genotype at codon 129 can deter-
mine the disease phenotype for human genetic prion
cases associated with pathogenic mutations [16]. In addi-
tion, variation in sCJD clinico-pathological phenotype
can be associated with specific genotypes [18].
The most significant finding with respect to codon 129
genotype and CJD is that all clinically probable and neu-
ropathologically confirmed cases of vCJD so far analysed
world-wide (n = 147 UK and 44 non-UK) have the MM
genotype and, therefore, this genotype is categorised as a
risk factor. However, there is evidence that other 129 gen-
otypes are susceptible to BSE/vCJD infection and that they
may develop disease after a longer incubation period than
in MM individuals. It is hypothesised that MV and VV
cases will occur in the future [19]. There are four reports
of transmission of vCJD infection via blood transfusion
from blood donors who later developed vCJD [3,4,20,21].
In three instances, the recipients developed clinical vCJD
and all three were homozygous MM at codon 129. In the
fourth case, there was no clinical or neuropathological
evidence of vCJD in the recipient, but disease-related
abnormal prion protein was found in the spleen and a
lymph node. This individual was MV at codon 129 and
may represent subclinical infection in a non-MM individ-
ual; it is impossible to know whether the individual
would have developed clinical vCJD if they had lived
longer [21]. In addition, two of three samples in an anon-BMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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ymous appendix study in the UK that were positive for
deposition of prion disease associated PrPSc were geno-
typed as VV [22].
Variation in the DNA sequence of PRNP may be linked to
other genetic changes separate to the prion protein itself,
such as promoter elements or regions more distant to the
PRNP gene. To understand more fully the control mecha-
nisms of PRNP gene expression, such as promoter activity,
extensive studies have been undertaken to examine the
region of chromosome 20 adjacent to the PRNP locus [23-
26]. Analysis of a 4.8 kb region around PRNP, identified 3
polymorphisms in areas that were predicted to control
gene expression [24].
This study involved the genetic analysis of CJD cases
referred to the National CJD Surveillance Unit during rou-
tine UK surveillance and a specific project to determine
normal population PRNP polymorphisms in the United
Kingdom.
Methods
Control DNA Samples
The Scottish Blood Donor controls (n = 778) were sup-
plied as 0.5 ml aliquots of frozen whole blood by Dr Ian
MacGregor (National Science Laboratory, Scottish
National Blood Transfusion Service) from samples taken
as part of a human prion disease study of blood markers
(covered by Multi-Centre Research Ethics Committee for
Scotland approval, reference MREC/02/10/46). There was
no ethical approval for full PRNP sequence analysis of
these samples.
DNA samples (UK DNA controls, n = 192) were pur-
chased from the European Collection of Cell Cultures
(ECACC) originating from donors in the UK cities of
Oxford and Birmingham. (Catalogue references: HRC-1
and HRC-2.)
For the normal population data, the Scottish Blood
Donor and UK DNA controls were genotyped for poly-
morphisms at M129V, and A117A, and the 24 bp deletion
in the N-terminus octapeptide repeat region (the three
most common polymorphic loci of PRNP). For the CJD
cases, we had PRNP sequence analysis data on 118 vCJD
and 309 sCJD patients.
Patient Samples
Patient blood samples were taken from individuals under
clinical review for suspected CJD, by venipuncture, into
citrate anticoagulant treated blood collection tubes. Once
received into the laboratory the blood was separated into
its major constituents as follows:
1. Whole blood was spun at 450 g for 10 minutes to
separate platelet rich plasma, buffy coat, and red
blood cells (RBC).
2. Platelets were removed from the plasma by two
washes in phosphate buffered saline (PBS) with cen-
trifugations at 16,000 g leaving platelet poor plasma.
This was stored at -80°C.
3. The buffy coat fraction was cleared of contaminat-
ing platelets by centrifugation at 180 g for 10 minutes,
then the RBC were removed by lysis with distilled
water and centrifugation at 180 g for 10 minutes.
Finally the buffy coat fraction was washed in PBS then
centrifuged at 100 g for 10 minutes before storing at -
80°C.
4. The RBC were washed twice with PBS, with centrif-
ugation at 180 g for 10 minutes each time. RBC were
stored at -80°C as a 50% solution in PBS.
DNA Extraction
DNA from cases and controls was prepared from 200 μl of
frozen whole blood by cell lysis and column purification
using the DNA Blood Mini Kit (Qiagen, UK) and stored at
-20°C.
PCR-RFLP Analysis
Amplification of the PRNP gene sequence (NCBI Acces-
sion: AL133396) by the polymerase chain reaction (PCR)
involved forward primer (5'-TGA TAC CAT TGC TAT GCA
CTC ATT C-3') and reverse primer (5'-GAC ACC ACC ACT
AAA AGG GCT GCA G-3') at 5 pmoles each per reaction
(Eurofins MWG Operon, Germany), that are specific for a
956 bp sequence. Each reaction contained 2 mM MgCl2
(Qiagen, UK), 0.2 mM dNTPs (Promega, UK), and 1 Unit
of Taq Polymerase (HotStarTaq, Qiagen, UK). The ther-
mal cycling program included an annealing temperature
step-down from 65°C to 60°C over ten cycles followed by
30 cycles at 60°C.
Confirmation of the codon 129 genotype was performed
by restriction enzyme digestion at 37°C with NspI (New
England Biolabs, UK). This enzyme cleaves the amplicon
at PRNP codon 155 and at codon 129 only when the latter
sequence codes for valine (-GTG-). This allowed for dis-
crimination of the three genotypes: MM, MV, and VV by
agarose gel electrophoresis and ethidium bromide stain-
ing, Figure 1. The presence of a 24 bp deletion in the
octapeptide repeat region could be observed from the
codon 129 genotyping agarose gel data due to an addi-
tional band shift for the restriction enzyme digest prod-
ucts. Codon 117 polymorphism genotype was
determined by restriction enzyme digestion of the same
PRNP  PCR product with PvuII (New England Biolabs,BMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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UK) at 37°C. This enzyme cleaves the wild-type PCR
product and not the codon 117 variant. In samples heter-
ozygous for the codon 117 polymorphism this enzyme
produces digest products of sizes 499 and 457 in addition
to the full length 956 bp PCR amplicon. (Figure 1)
Sequencing
If consent from the patient, or relative, had been obtained
for full genetic analysis then the PCR product was
sequenced by fluorescent dye-primer chemistry (Thermo
Sequenase Primer Cycle Sequencing Kit, Amersham Bio-
sciences, UK) using an ALF-Express DNA Sequencer
(Amersham Biosciences, UK). PCR products were purified
Detection of PRNP polymorphisms Figure 1
Detection of PRNP polymorphisms. Panels A and B: Genotyping by PCR amplification of PRNP and restriction enzyme 
digest. (Mw: 100 bp molecular weight ladder (dark band 600 bp); MV, MM, VV: codon 129 genotypes; WT: wild-type codon 
117 genotype; MUT: heterozygous for codon 117 polymorphism) Panels C, D, and E: Electropherograms for polymorphisms 
detected by sequence analysis. (Arrows point to heterozygous base position.)BMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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using a QIAquick PCR Purification Kit (Qiagen, UK) to
remove excess primers and other PCR reagents. Four Cy5
labelled sequencing primers were used to give at least 2-
fold coverage of the entire ORF (5'-AGG TGG CAC CCA
CAG TCA GT-3'; 5'-CTA TGC ACT CAT TCA TTA TG-3'; 5'-
CCT CAA GCT GGA AAA AGA TTA G-3'; 5'-CGA TAG TAA
CGG TCC TCA TA-3'). Sequencing reaction products were
electrophoresed through ReproGel Long Read acrylamide
gels (Amersham Biosciences, UK). ALFwin Software
(Amersham Biosciences, UK) was used to align the
sequence data with a reference sequence and each codon
of the ORF was visually checked by two individuals. This
method allows for identification of novel polymorphisms
rather than only checking for known ORF sequence
changes. (Figure 1)
Statistical Analysis
Analysis was undertaken through the use of R (v2.9.1) (R
Development Core Team (2009). R: A language and envi-
ronment for statistical computing. R Foundation for Sta-
tistical Computing, Vienna, Austria. ISBN 3-900051-07-0.
URL: http://www.R-project.org).
Results
Variant CJD PRNP Sequence Data
Table 1 shows the results of PRNP gene sequence analysis
in vCJD cases where material and specific consent was
available. 147 confirmed cases were genotyped at codon
129 and all were methionine homozygotes (MM). Com-
plete sequence analysis of the PRNP ORF was performed
for 118 cases and found five individuals with genetic var-
iation. Two had a synonymous (silent) polymorphism at
codon 202 (GAC-aspartic acid to GAT-aspartic acid;
D202D), two had a non-synonymous change at codon
219 (GAG-glutamic acid to AAG-lysine; E219K), and one
had a 24 bp deletion (classified as DelR34 according to
[27]). The DelR34 and the two D202D patients fulfilled
the diagnostic criteria [28] for definite vCJD. The two
patients with E219K genotype did not have a post mortem
and were classified as probable vCJD. The E219K muta-
tion has not been seen in white Caucasian populations
and has so far only been detected in populations from
Asian and the Pacific [29]. The two individuals with the
E219K genotype found in this study were not of white
Caucasian origin (the specific ancestral origin is
unknown).
Sporadic CJD Sequence Data
Sequence variation for 309 confirmed sCJD patients is
shown in Table 2. Codon 129 genotyping produced allele
frequencies similar to that expected for this disease from
other studies [13,18] and to the overall figures published
by the UK National CJD Surveillance Unit (MM 63%, MV
19%, VV 18%; n = 647) (http://www.cjd.ed.ac.uk; Annual
Report 2008). Complete sequence analysis on these
patients found thirteen with the silent polymorphism at
codon 117 (GCA-alanine to GCG-alanine; A117A), which
included one individual with an additional silent poly-
morphism at codon 68 (P68P), and four cases with a 24
bp deletion in the octapeptide repeat region. Of these 17
patients 13 were classified as definite and four as probable
sCJD according to the diagnostic criteria. In addition, one
patient was found to have a non-synonymous polymor-
phism at codon 167 (GAT-aspartic acid to GGT-glycine;
D167G). There was nothing in the clinical phenotype sug-
gesting that this could be a causative mutation of gCJD
and the patient was classified as probable "sporadic CJD".
Neuropathological analysis confirmed sporadic CJD with
type 1 prion protein isoform present, and genetic analysis
showed methionine homozygosity at codon 129 of PRNP.
Control Codon 129 Genotype Data
Codon 129 genotype frequencies are given in Table 2 for
samples from the UK DNA and Scottish Blood Donor
Table 1: PRNP gene sequence variation in vCJD cases
Codon Number Tested Genotype Data
129 (Met/Val) 147 All cases MM
4 (blood transfusion associated infections) MM (n = 3)
MV (n = 1)*
2 (appendix tissue) VV (n = 2)**
202 (Asp/Asp) 118 DD (n = 2)
219 (Glu/Lys) 118 EK (n = 2)
24 bp deletion 118 DelR34 (n = 1)
* Non-clinical, non-neuropathologically confirmed case
** From anonymous screening program for vCJD associated PrPSc depositionBMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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controls. Together with the published Edinburgh/Belfast
blood donors, the figures are similar across the three
groups and combined (n = 1158) give the predicted UK
national genotype frequencies of 44.1% (MM), 44.5%
(MV), and 11.4% (VV). As there is a significant difference
in age at onset between vCJD and sCJD, and that gender
may influence sCJD survival [30], the Scottish Blood
Donor data was stratified into four groups according to
age (17-30, 31-40, 41-50, and 51-69), Figure 2, and by
sex, Figure 3. Statistical analysis (Chi-Squared test) indi-
cated that there were no age (p = 0.5774, 0.1270, and
0.4781) or gender (p = 0.2228, 0.9884, and 0.7527)
effects determined by genotype at codon 129, or 117, or
by the presence of a 24 bp deletion, respectively.
Statistical Comparison (Chi Squared Testing) of Control 
and Case Data
Comparisons made between codon 129 genotype fre-
quencies for sCJD, vCJD, and the two control groups
showed statistically significant differences (P < 0.001,
Table 3). There was no significant difference in genotype
between the two control groups. There was no selection
bias for the sequenced sCJD patients as there was no sig-
nificant difference between that group and the larger
group of UK National CJD Surveillance Unit sCJD
patients that have been genotyped.
The frequencies of A117A and 24 bp deletion were not sta-
tistically different from the control data.
Analysis of the genotype frequencies of D202D and
E219K could not be done as they were only found in vCJD
and not in the controls, as the latter were not sequenced.
Discussion
Analysis of PRNP in sCJD, vCJD and controls has high-
lighted the clear primary role in disease susceptibility for
the codon 129 genotype and has provided a base-line for
the healthy population for future vCJD susceptibility pre-
dictions. In addition, the presence of genetic variation
(D202D and E219K) in vCJD that is not seen in sCJD sug-
gests possible additional risk factors. A novel non-synon-
ymous polymorphism (D167G) in a case of suspected
sCJD has also underlined the need for PRNP  genetic
screening of patients.
For accurate diagnosis of the various forms of human CJD,
and especially to identify inherited genetic forms, DNA
sequence analysis of the PRNP open reading frame (ORF)
is necessary. Aside from the detection of any pathogenic
mutations, this provides data on any polymorphic resi-
dues present, important for full characterisation of non-
genetic cases [18]. The majority of non-pathogenic poly-
morphisms are rare.
Codon 129 genotype frequency data show the clear differ-
ence between CJD cases and controls with a reduction in
the frequency of MV (21.4%) for sCJD cases compared to
the controls (~45%), and 100% MM cases in vCJD. As the
control genotype frequencies were not found to vary by
age the case data is unlikely to be due to the significant dif-
ference in average age at onset between vCJD and sCJD. If
Table 2: PRNP gene sequence variation in sCJD cases and controls
PRNP Variation 309 sCJD Patients 192 UK DNA Controls 778 Scottish Blood Donor Controls
Codon 129 (Met/Val) MM (n = 184; 59.5%)
MV (n = 66; 21.4%)
VV (n = 59; 19.1%)
MM (n = 90; 46.9%)
MV (n = 87; 45.3%)
VV (n = 15; 7.8%)
MM (n = 337; 43.3%)
MV (n = 344; 44.2%)
VV (n = 97; 12.5%)
Codon 117 (Ala/Ala) n = 13; 4.2%
(10.4% of MV/VV cases)
n = 9; 4.7%
(10.3% of MV/VV cases)
n = 47; 6.0%
(10.7% of MV/VV cases)
24 bp Deletion n = 4; 1.3%
Deletion Class
R34 (n = 3)
R3 (n = 1)
n = 1; 0.5%
Deletion Class
R2 (n = 1)
n = 12; 1.5%
Deletion Class
R34 (n = 12)
Codon 167
(Asp/Gly)
DG (n = 1; 0.32%) (no sequence data available) (no sequence data available)
Codon
68
(Pro/Pro)
PP (n = 1; 0.32%) (no sequence data available) (no sequence data available)BMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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PRNP polymorphisms in Scottish Blood Donors Figure 2
PRNP polymorphisms in Scottish Blood Donors. Codon 129 and PRNP polymorphism frequency in relation to age of 
Scottish Blood Donors (n = 778).
Codon 129 and sex of Scottish Blood Donors Figure 3
Codon 129 and sex of Scottish Blood Donors. Codon 129 genotype frequency in relation to sex of Scottish Blood 
Donors (n = 778, male = 456 (solid bars), female = 322 (hatched bars)).BMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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clinical vCJD continues to manifest only in MM genotype
individuals then the mathematical models for predicting
the total epidemic size can use the population MM fre-
quency of 44.1% in the UK population, generated by this
study.
Other than M129V the two most common PRNP variants
in Caucasian populations are: A117A (frequency ~5%),
and a 24 bp deletion in the repeat expansion region
(~1%). Full PRNP sequencing of 118 confirmed UK vCJD
patients found five with PRNP polymorphisms: two with
E219K, two with D202D, and one with a 24 bp deletion
(DelR34). The codon 117 polymorphism has not been
found, as this is linked to the valine allele at codon 129,
and all vCJD cases to date have been 129-MM.
D202D  is a synonymous polymorphism and therefore
there is no resulting change in prion protein amino acid
sequence. No data are available on normal population
frequency and the only record of its appearance has been
in single French cases of sCJD and iCJD related to human
Growth Hormone treatment (Dr N Delasnerie-Laupretre -
personal communication). There are no structural
changes to the prion protein itself and so this DNA
sequence alteration would not directly affect protein fold-
ing kinetics in a potentially disease causing manner. Mis-
sense DNA sequence change GAC (glutamic acid) to AAC
(asparagine) at this codon (D202N) is associated with a
disease phenotype of Gerstmann-Sträussler-Scheinker
syndrome (GSS) a genetic form of human prion disease
[31]. The D202D change may be linked with a haplotype,
as yet undefined, that alters susceptibility via an alterna-
tive route such as differential expression of PrP. This may
possibly be the reason why ~2% of tested vCJD cases have
been found with this polymorphism. Until control popu-
lation frequencies are available this possibility remains
hypothetical.
E219K is a non-synonymous, missense mutation with a
change in amino acid and, therefore, the possibility of
protein structural differences which may be linked to an
increase in disease susceptibility. This polymorphism has
not been found in Western European populations and has
only been investigated in detail, with regards to CJD, in
Japan [32] and Korea [33] where approximately 12% and
8% respectively of the population carry the lysine (K)
allele. These studies indicated that E219K influenced the
clinical phenotype of GSS in cases with the P102L muta-
tion [34], and found it was a protective factor to sCJD as
no confirmed cases of sCJD in Japan or Korea carry the
polymorphism. In the two vCJD cases found in our study
with E219K, there were no clinico-pathological differ-
ences from the other vCJD cases. These patients were of
non-Caucasian origin, therefore their genetic ancestry
may originate from populations where E219K is more
common than the UK [29]. There remains a possibility
that the presence of this polymorphism may increase sus-
ceptibility to vCJD. A transgenic mouse model suggests
that the lysine (K) allele PrPC is more susceptible than the
glutamic acid (E) allele to conversion to PrPSc [35].
24 bp deletions were found in healthy individuals, sCJD,
and vCJD patients at similar frequencies. It is therefore
proposed that this genetic variation does not influence the
disease state or susceptibility, even though the PrPC
formed is significantly different at the metal binding
Table 3: Statistical analysis of PRNP polymorphism frequencies
Chi-Squared Test - P value
Comparison Codon 129 Codon 117 24 bp Deletion
Sequenced sCJD (n = 309) vs.
All NCJDSU sCJD cases (n = 647)
0.582 NA NA
UK DNA Controls (n = 192) vs.
Scottish Blood Donors (n = 778)
0.185 0.584 0.452*
Sequenced sCJD (n = 309) vs.
UK DNA Controls (n = 192)
<0.001 0.975 0.700*
Sequenced sCJD (n = 309) vs.
Scottish Blood Donors (n = 778)
<0.001 0.295 0.978*
Sequenced vCJD (n = 118) vs.
Scottish Blood Donors (n = 778)
<0.001 NA 0.861*
*: Chi-Squared approximation may be incorrect due to low numbers; NA: no comparison could be madeBMC Medical Genetics 2009, 10:146 http://www.biomedcentral.com/1471-2350/10/146
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domain of the N-terminus, as shown by other studies
[36,37]. Deletion of two 24 bp repeats in this region has
been linked to a familial form of CJD [38].
There have been no reported instances of the D167G sCJD
polymorphism associated with familial human prion dis-
ease. Evidence for this event to be the cause of a genetic
form of CJD in this patient is twofold:
1. The replacement of a large hydrophilic amino acid
for a small hydrophobic one may disturb the physical
properties of the prion protein and thus accelerate for-
mation of the disease associated form (PrPSc).
2. Transgenic mouse studies propose that codon 167
may be in a region of the prion protein structure where
chaperone molecules bind and accelerate disease
transmission [39].
Without the additional evidence of further affected mem-
bers of the family with the mutation or data on a healthy
control population there is no direct proof of the associa-
tion of D167G and CJD.
Conclusions
This study has produced genotype frequencies for the
most common PRNP genetic variants in the largest cohort
of healthy individuals from the UK so far published, and
in groups of patients with vCJD and sCJD. These data can
act as a benchmark for studying the genotype frequency
variation found in human prion disease in the UK. DNA
sequence analysis of vCJD patients has revealed the extent
of genetic variation within this population to include
potential new risk factors, and sCJD analysis has uncov-
ered a novel PRNP polymorphism.
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